BioCryst Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, BioCryst Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#553 of 15,742 sponsors by registered trial count).
BioCryst Pharmaceuticals: 29 sponsored US clinical trials, 2 recruiting.
BioCryst Pharmaceuticals sponsors 29 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 24 completed. 6 of these trials are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gout, with 2 trials.
Top-decile sponsor footprint
BioCryst Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#553 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 27 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
29 total, page 1 of 1
A Study of Avoralstat In Participants With Diabetic Macular Edema
NCT07228559
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
NCT03800173
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
NCT03472040
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
NCT03485911
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
NCT02635724
Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza
NCT02369159
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
NCT02303626
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
NCT01407874
Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol
NCT01265264
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
NCT01129648
A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza
NCT00958776
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
NCT00957996
Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout
NCT00985127
A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza
NCT00705406
Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)
NCT00640523
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
NCT00610935
Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
NCT00453999
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
NCT00501735
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
NCT00419263
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
NCT00419081
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
NCT00289549
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
NCT00098332
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
NCT00289562
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
NCT00095381
BCX-1777 in Treating Patients With Refractory Cancer
NCT00073944
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00061880
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
NCT00035022
A Study of Peldesine (BCX-34) in HIV-Infected Patients
NCT00002237
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 14 |
| Phase 3 | 6 |
Therapeutic Areas
What is open in the BioCryst Pharmaceuticals pipeline
2 recruiting of 29 indexed (7% open); 24 completed (83%).
Phase mix: 6 late (III/IV) vs 23 early (I/II) (early-phase heavy).
Top condition: Gout (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BioCryst Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 29 registered trials and 7% open enrollment, not the therapeutic-area sidebar.
BioCryst Pharmaceuticals sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 29 trials (± recruiting share)
- BeOne Medicines · 29 trials · 79% recruiting
- California Pacific Medical Center Research Institute · 29 trials · 10% recruiting
- Center for International Blood and Marrow Transplant Research · 29 trials · 24% recruiting
- Craig Hospital · 29 trials · 21% recruiting
Sponsors near 7% open enrollment (± trial volume)
- Genentech · 7% recruiting · 332 trials
- H. Lundbeck A/S · 7% recruiting · 72 trials
- Agios Pharmaceuticals · 7% recruiting · 44 trials
- Wake Forest University · 7% recruiting · 100 trials
Related
What to do with this BioCryst Pharmaceuticals page
29 registered trials is a research-attention snapshot, not an endorsement of BioCryst Pharmaceuticals or any single study.
- 2 of BioCryst Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Gout is the condition BioCryst Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gout trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioCryst Pharmaceuticals pipeline card: 29 registered trials from official public datasets.Report a data error.